BMY vs. ZTS, PFE, ABBV, MRK, JNJ, LLY, SNY, ABT, VRTX, and REGN
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Zoetis (ZTS), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Eli Lilly and (LLY), Sanofi (SNY), Abbott Laboratories (ABT), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "pharmaceutical preparations" industry.
Bristol-Myers Squibb vs.
Zoetis (NYSE:ZTS) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.
In the previous week, Bristol-Myers Squibb had 14 more articles in the media than Zoetis. MarketBeat recorded 20 mentions for Bristol-Myers Squibb and 6 mentions for Zoetis. Zoetis' average media sentiment score of 0.88 beat Bristol-Myers Squibb's score of 0.08 indicating that Zoetis is being referred to more favorably in the media.
Bristol-Myers Squibb received 190 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.57% of users gave Zoetis an outperform vote while only 67.86% of users gave Bristol-Myers Squibb an outperform vote.
Zoetis pays an annual dividend of $1.50 per share and has a dividend yield of 0.9%. Bristol-Myers Squibb pays an annual dividend of $2.28 per share and has a dividend yield of 3.5%. Zoetis pays out 33.9% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out 66.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 9 consecutive years and Bristol-Myers Squibb has increased its dividend for 16 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Zoetis has a net margin of 25.59% compared to Bristol-Myers Squibb's net margin of 15.95%. Bristol-Myers Squibb's return on equity of 51.75% beat Zoetis' return on equity.
Zoetis presently has a consensus target price of $221.14, suggesting a potential upside of 29.14%. Bristol-Myers Squibb has a consensus target price of $78.62, suggesting a potential upside of 18.54%. Given Zoetis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Zoetis is more favorable than Bristol-Myers Squibb.
90.2% of Zoetis shares are held by institutional investors. Comparatively, 75.5% of Bristol-Myers Squibb shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.
Zoetis has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.
Summary
Zoetis beats Bristol-Myers Squibb on 13 of the 21 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
